Abstract 386P
Background
Sac-TMT (also known as SKB264/MK-2870) is a TROP2 ADC developed with a hydrolytically cleavable linker to conjugate the payload T030, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio of 7.4. The pivotal phase III OptiTROP-Breast01 study (NCT05347134), presented at the 2024 ASCO meeting, demonstrated improved survival outcomes with sac-TMT over chemotherapy in patients with pretreated advanced TNBC. This exploratory analysis from OptiTROP-Breast01 study evaluates the impact of prior PD-(L)1 inhibitors on clinical outcomes.
Methods
Patients with locally recurrent or metastatic TNBC who had received two or more prior therapies, with at least one given in the metastatic setting, were randomized to receive either sac-TMT or treatment of physician’s choice (TPC: eribulin, capecitabine, gemcitabine, or vinorelbine). The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR).
Results
As of Nov 30, 2023, prior PD-(L)1 inhibitors were received in 24.6% (32/130) of patients treated with sac-TMT and 27.1% (36/133) treated with TPC. Clinical benefit was observed with sac-TMT versus TPC in this subgroup. The median PFS by BICR was 5.6 versus 2.7 months (HR 0.31; 95% CI 0.17-0.54), and objective response rate (ORR) by BICR was 56.3% versus 5.6%. For those patients who didn’t receive prior PD-(L)1 inhibitors, efficacy outcomes were similarly improved with sac-TMT versus TPC. The median PFS was 7.2 versus 2.3 months (HR 0.34; 95% CI 0.23-0.48), and ORR was 41.8% versus 14.4%. Safety data in the sac-TMT arm were similar between patients with or without prior PD-(L)1 inhibitors.
Conclusions
This exploratory analysis suggests that treatment with sac-TMT results in better outcomes than TPC for previously treated locally recurrent or metastatic TNBC patients regardless of prior PD-(L)1 therapy, supporting sac-TMT as an effective treatment option in this population.
Clinical trial identification
NCT05347134; first posted on April 26, 2022.
Editorial acknowledgement
Legal entity responsible for the study
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China.
Funding
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China.
Disclosure
X. Jin; Y. Diao; G. Liu; J. Ge: Financial Interests, Personal, Full or part-time Employment: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
404P - Real-world analysis on molecular targeted therapy recommendations and attainment rates in cancer gene panel testing for metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 15
405P - HRD biomarkers in blood samples from BRCA1/BRCA2-associated advanced breast cancer (BC) patients (pts)
Presenter: Violeta Serra
Session: Poster session 15
406P - Genomic landscape of endocrine therapy (ET)-resistant BRCA1/2 and PALB2 altered metastatic breast cancer (mBC)
Presenter: Abeid Omar
Session: Poster session 15
407P - Genomic profiling and prediction role of the molecular tumor burden index in advanced HR+HER2- breast cancer
Presenter: Xuenan Peng
Session: Poster session 15
408P - Characterizing the genomic landscape of breast cancer in an Irish cohort of patients
Presenter: Georgia Thodi
Session: Poster session 15
409P - Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up
Presenter: Jo De Vos
Session: Poster session 15
410P - Breast cancer lighthouse non-interventional hybrid real-world study: Molecular characterization and 2-year effectiveness data
Presenter: Angela Margarida Nogal Dias
Session: Poster session 15
412P - Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02
Presenter: Hope Rugo
Session: Poster session 15
413P - Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors
Presenter: Timothy Anthony Yap
Session: Poster session 15